前列腺影像报告和数据系统第2版检测前列腺癌的诊断效能:系统评价与诊断性Meta分析
该系统评价纳入21项研究(3857例患者),汇总PI-RADSv2检测前列腺癌的敏感度为0.89(95%CI 0.86-0.92),特异度为0.73(95%CI 0.60-0.83)。在6项头对头比较研究中,PI-RADSv2汇总敏感度为0.95(95%CI 0.85-0.98),高于PI-RADSv1的0.88(95%CI 0.80-0.93)(p=0.04);两者汇总特异度无显著差异(0.73 [95%CI 0.47-0.89] vs 0.75 [95%CI 0.36-0.94],p=0.90)。
要点
- PI-RADSv2检测前列腺癌汇总敏感度0.89(95%CI 0.86-0.92),特异度0.73(95%CI 0.60-0.83)。
- 头对头研究中PI-RADSv2汇总敏感度高于PI-RADSv1(0.95 vs 0.88,p=0.04)。
- 两者汇总特异度无显著差异(p=0.90)。
核心结论
- PI-RADSv2检测前列腺癌表现出良好效能。
- PI-RADSv2汇总敏感度高于PI-RADSv1,而特异度无显著差异。
研究设计与样本
- 系统评价与诊断性Meta分析,检索MEDLINE和EMBASE数据库至2016年12月7日。
- 纳入使用PI-RADSv2检测前列腺癌并以前列腺切除术或活检为参考标准的诊断准确性研究。
- 共纳入21项研究、3857例患者;采用QUADAS-2工具由两名独立评价者评估方法学质量。
主要发现
- PI-RADSv2检测前列腺癌的汇总敏感度为0.89(95%CI 0.86-0.92),汇总特异度为0.73(95%CI 0.60-0.83)。
- 前列腺癌患者比例、磁场强度和参考标准是影响异质性的显著因素(p<0.01)。
- 多项亚组分析显示结果一致。
- 6项头对头比较研究中,PI-RADSv2汇总敏感度为0.95(95%CI 0.85-0.98),高于PI-RADSv1的0.88(95%CI 0.80-0.93)(p=0.04)。
- 头对头比较中,PI-RADSv2与PI-RADSv1的汇总特异度无显著差异(0.73 [95%CI 0.47-0.89] vs 0.75 [95%CI 0.36-0.94],p=0.90)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: In 2015, the updated Prostate Imaging Reporting and Data System version 2 (PI-RADSv2) for the detection of prostate cancer (PCa) was established. Since then, several studies assessing the value of PI-RADSv2 have been published. OBJECTIVE: To review the diagnostic performance of PI-RADSv2 for the detection of PCa. EVIDENCE ACQUISITION: MEDLINE and EMBASE databases were searched up to December 7, 2016. We included diagnostic accuracy studies that used PI-RADSv2 for PCa detection, using prostatectomy or biopsy as the reference standard. The methodological quality was assessed by two independent reviewers using the Quality Assessment of Diagnostic Accuracy Studies-2 tool. Sensitivity and specificity of all studies were calculated. Results were pooled and plotted in a hierarchical summary receiver operating characteristic plot with further exploration using meta-regression and multiple subgroup analyses. Head-to-head comparison between PI-RADSv1 and PI-RADSv2 was performed for available studies. EVIDENCE SYNTHESIS: Twenty-one studies (3857 patients) were included. The pooled sensitivity was 0.89 (95% confidence interval [CI] 0.86-0.92) with specificity of 0.73 (95% CI 0.60-0.83) for PCa detection. Proportion of patients with PCa, magnetic field strength, and reference standard were significant factors affecting heterogeneity (p<0.01). Multiple subgroup analyses showed consistent results. In six studies performing head-to-head comparison, PI-RADSv2 demonstrated higher pooled sensitivity of 0.95 (95% CI 0.85-0.98) compared with 0.88 (95% CI 0.80-0.93) for PI-RADSv1 (p=0.04). However, the pooled specificity was not significantly different (0.73 [95% CI 0.47-0.89] vs 0.75 [95% CI 0.36-0.94], respectively; p=0.90). CONCLUSIONS: PI-RADSv2 shows good performance for the detection of PCa. PI-RADSv2 has higher pooled sensitivity than PI-RADSv1 without significantly different specificity. PATIENT SUMMARY: We reviewed all previous studies using Prostate Imaging Reporting and Data System version 2 (PI-RADSv2) for prostate cancer detection. We found that the updated PI-RADSv2 shows significant improvement compared with the original PI-RADSv1.
引用
- Woo S, Suh CH, Kim SY, et al. Diagnostic Performance of Prostate Imaging Reporting and Data System Version 2 for Detection of Prostate Cancer: A Systematic Review and Diagnostic Meta-analysis. Eur Urol. 2017. PMID: 28196723. doi:10.1016/j.eururo.2017.01.042
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。